Drugs / OVEMOTIDE
OVEMOTIDE
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03546361 | Jul 2019 → Jan 2026 overdue | non-small cell lung carcinoma | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT00601094 | Feb 2009 → May 2017 | lung cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00798629 | Nov 2008 → Apr 2012 | cutaneous melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00923195 | Dec 2008 → Aug 2011 | melanoma, skin cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00706992 | Jun 2008 → Nov 2012 | melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OVEMOTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL263441 ↗ |
| Known as | (leu27)-melan-a, mart 1 (26-35) | ChEMBL registry synonym — accepted as the source's own label CHEMBL263441 ↗ |
| Known as | Ad-CCL21-DC | “Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.” NCT00601094 ↗ |
| Known as | Autologous dendritic cell-adenovirus CCL21 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00798629 ↗ |
| Known as | Elagigiltv | ChEMBL registry synonym — accepted as the source's own label CHEMBL263441 ↗ |
| Known as | Gp100:280-288(288v) peptide | ChEMBL registry synonym — accepted as the source's own label CHEMBL263441 ↗ |
| Known as | MART-1:26-35(27L) peptide | “Patients will be randomized to receive either the gp100:154-162 peptide or the MART-1:26-35(27L) peptide emulsified in incomplete Freund's adjuvant.” NCT00923195 ↗ |
| Known as | Melan-a(aa26-35*a27l)) | ChEMBL registry synonym — accepted as the source's own label CHEMBL263441 ↗ |
| Known as | MPS-21 | ChEMBL registry synonym — accepted as the source's own label CHEMBL263441 ↗ |
| Known as | Ovemotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL263441 ↗ |
| Action | Activate | “The procedure also uses one of two vaccines-the anti-MART-1 peptide or the anti-gp100 peptide-to stimulate cells in the immune system” NCT00923195 ↗ |
| Modality | Cell therapy | “Patients undergo leukapheresis to obtain leukocytes for generation of autologous dendritic cells (DC). Adenovirus carrying the CCL21 gene is added to the dendritic cells to...” NCT00601094 ↗ |
| Route | Subcutaneous | “MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 subcutaneously (SC)” NCT00706992 ↗ |